{"id":"azd9567","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This inhibition leads to a reduction in the activation of downstream signaling pathways, which can contribute to the development of various diseases. By targeting the PI3K delta subunit, AZD9567 aims to modulate the immune response and potentially treat certain types of cancer.","oneSentence":"AZD9567 is a small molecule that inhibits the activity of the PI3K delta subunit.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:30:30.400Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory chronic lymphocytic leukemia (CLL)"}]},"trialDetails":[{"nctId":"NCT04556760","phase":"PHASE2","title":"Study to Assess the Effect on Glucose Homeostasis of Two Dose Levels of AZD9567, Compared to Prednisolone, in Adults With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-11-26","conditions":"Diabetes Mellitus, Type 2","enrollment":46},{"nctId":"NCT03368235","phase":"PHASE2","title":"Early Phase Study to Assess Efficacy and Safety of AZD9567 Versus Prednisolone in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-01-18","conditions":"Rheumatoid Arthritis","enrollment":21},{"nctId":"NCT02512575","phase":"PHASE1","title":"A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD9567.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-11-18","conditions":"Safety, Tolerability, Pharmacokinetics","enrollment":72},{"nctId":"NCT02760316","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-05-02","conditions":"Rheumatoid Arthritis","enrollment":64}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AZD9567","genericName":"AZD9567","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZD9567 is a small molecule that inhibits the activity of the PI3K delta subunit. Used for Relapsed or refractory chronic lymphocytic leukemia (CLL).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}